NCT03441191 is a NA clinical trial of Audiovisual Stimulation in Insomnia Chronic, sponsored by University of Washington.

Who is sponsoring NCT03441191?

NCT03441191 is sponsored by University of Washington.

What drugs are being tested in NCT03441191?

Interventions in NCT03441191: Audiovisual Stimulation.

What condition does NCT03441191 study?

NCT03441191 studies Insomnia Chronic, Osteoarthritis, Pain, Chronic.

Is NCT03441191 still recruiting?

NCT03441191 is currently completed. Last updated 22 February 2018.

Last reviewed 2018-02-22 · How we verify

NCT03441191

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Audio-visual Stimulation for Sleep Promotion in Older Adults With Osteoarthritis Pain

Completed NA Last updated 22 February 2018

What this trial tests

NA trial testing Audiovisual Stimulation in Insomnia Chronic in 30 participants. Completed in 1 November 2016.

Timeline

1 October 2014

Primary endpoint
1 November 2016

1 November 2016

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	1 October 2014
Primary completion	1 November 2016
Estimated completion	1 November 2016

Drugs / interventions tested

Audiovisual Stimulation

Conditions studied

Insomnia Chronic — all drugs for Insomnia Chronic →
Osteoarthritis — all drugs for Osteoarthritis →
Pain, Chronic — all drugs for Pain, Chronic →

Sponsor

University of Washington

Who can join

60 and older, any sex, with Insomnia Chronic or Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background and Purpose: The purpose of the study is to test the efficacy of an audio-visual stimulation program for sleep promotion in adults with chronic pain. The hypothesis is that hyper-arousal plays an important role in insomnia. Brainwave entrainment from 8 to 1 Hz reduces arousal, and thereby improves sleep. Improved sleep may change how people perceive pain. Methods: Using a double-blind, randomized controlled trial design, we plan to enroll 30 adults (21-65 years old) experiencing both nonmalignant pain and insomnia. Exclusion criteria include: seizure disorder, sleep disorder, and night shift workers. After a one-week baseline measure, participants will be randomized to intervention or placebo group. Participants in both groups will be asked to self-administer the audio-visual stimulation program every night at bedtime for one month. Upon completion, post intervention measures will be collected.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Open-Loop Audiovisual Stimulation Induces Delta EEG Activity in Older Adults With Osteoarthritis Pain and Insomnia.
Tang HJ, McCurry SM, Riegel B, Pike KC, et al · · 2019 · cited 7× · PMID 30862174 · DOI 10.1177/1099800419833781

Verify or expand the search:

Other trials of Audiovisual Stimulation

Trials testing the same drug.

NCT05703360 — Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance · NA · not yet recruiting
NCT03569865 — Audio-visual Stimulation: Sleep Dose Response · NA · completed

Other recruiting trials for Insomnia Chronic

Currently open trials in the same condition.

NCT07387406 — Sleep Learning Education and Empowerment for Older Korean Immigrants · NA · recruiting
NCT07089797 — Nurse-supported Mobile App for Self-help CBT-I in Informal Cancer Caregivers · NA · recruiting
NCT06736548 — Sleep Treatment Education Program for Cancer Survivors: STEP-Together · NA · recruiting
NCT06926348 — Assessment of Usability and Preliminary Effectiveness of a Digital Sleep Aid in an Italian Sample · NA · recruiting
NCT06767137 — Comparative Efficacy of BRT and CBT-I for Insomnia · NA · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03441191 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 22 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03441191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing